Enliven Therapeutics (NASDAQ:ELVN) Earns Buy Rating from Analysts at BTIG Research

BTIG Research began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note released on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $42.00 price objective on the stock.

Several other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and a consensus target price of $38.25.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $23.15 on Friday. The business has a 50 day moving average price of $26.56 and a 200 day moving average price of $24.16. The company has a market capitalization of $1.13 billion, a P/E ratio of -12.18 and a beta of 1.02. Enliven Therapeutics has a 1-year low of $10.90 and a 1-year high of $30.03.

Insider Transactions at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 4,250 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Samuel Kintz sold 924 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $27,720.00. Following the completion of the transaction, the chief executive officer now owns 1,002,892 shares of the company’s stock, valued at $30,086,760. The trade was a 0.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 129,195 shares of company stock worth $3,581,772 over the last ninety days. 29.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quest Partners LLC increased its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock valued at $668,000 after buying an additional 2,944 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after buying an additional 3,518 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after buying an additional 3,559 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.